Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 7707 results

  1. The Stak for knee stretching following knee replacement or injury or to treat osteoarthritis

      Status ...

    Medical technologies guidance
    Topic selection

  2. DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants

      Status ...

    Diagnostics guidance
    Topic selection

  3. URO17 for testing suspected bladder cancer

      Status ...

    Diagnostics guidance
    Topic selection

  4. RenalSense Clarity RMS for acute kidney injury MT601 (MIB256)

      Status ...

    Medical technologies guidance
    Topic selection

  5. Botulinum toxin type A for preventing episodic migraine ID 6450

    Awaiting development [GID-TA11505] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Awaiting development [GID-TA11486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]

    Awaiting development [GID-TA11565] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

      Status ...

    Technology appraisal guidance
    Topic selection

  14. IgPro20 for treating dermatomyositis TS ID 12014

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development [GID-TA11438] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development